TEISSEYRE THOMAS sold $6K of HYPR

Hyperfine HYPR reported preliminary Q3 2026 revenue of $6.0M, beating estimates and up 53% sequentially. Shares rose 9% premarket. Net cash burn improved 29% QoQ. Full-year revenue guidance remains $20M-$22M, with cash burn expected to decline 10% YoY. Results will be detailed on Nov 9, 2026.

Hyperfine (HYPR) reported preliminary Q3 revenue of $6.0M, exceeding the consensus estimate of $5.13M. This marks a 53% sequential increase from Q2 2026. The company's shares rose nearly 9% in pre-market trading.

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu

Hyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered

Hyperfine (Nasdaq: HYPR) says it has started launching its next-generation Swoop portable MRI system (Model 2) in Europe after CE mark and UKCA approval. The company also reports Model 2 inclusion in UniHA’s procurement listing for France’s public hospitals and plans broader European availability via distribution partners in 2026.